5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The High Content Screening Market is segmented by Type of Product (Instruments, Consumables, Software, and Other Products), Application, End User, and Geography.
2018 - 2026
Fastest Growing Market:
Under the conventional method of toxicity studies, large libraries are screened in search of potential drug candidates. This method is expensive, resource- and time-consuming, and has a low success rate. Consequently, high content screening (HCS) solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in-vitro toxicity testing by reducing the time and cost.
High content screening (HCS) is a method that is used in biological research and drug discovery to identify substances, such as small molecules, peptides, or RNAi, that alter the phenotype of a cell in the desired manner. High content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.
|Primary and Secondary Screening|
|Target Identification and Validation|
|By End User|
|Pharmaceutical and Biotechnology Companies|
|Academic and Government Institutions|
|Contract Research Organization|
Report scope can be customized per your requirements. Click here.
Based on the product segment, the high content screening market is further segmented into instruments, consumables, and software and services. Among all high content screening products, the instrument segment occupies the largest share of the market. The large share of this segment is attributed to advances in instrumentation and automation techniques and the high prices of HCS instruments. Companies are developing automated solutions such as instruments with advanced visualization capability, in line with the enhanced software platform. These advances are boosting the market growth. In January 2017, PerkinElmer Inc. launched the Vectra Polaris automated quantitative pathology imaging system. This multi-modal tissue imaging system enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches. The increasing funds for product development and increasing use of the instruments are boosting the segment.
To understand key trends, Download Sample Report
The high content screening market in Asia-Pacific is expected to register the highest CAGR over the forecast period. Factors, such as increasing drug discovery research, government initiatives, growing focus of multinational companies on emerging markets, and developing R&D infrastructure, are driving the growth of the HCS market in this region. Japan and China are expected to witness significant growth during the forecast period, as many research and development programs are carried out by manufacturers to improve the cell analyzers and flow cytometers in the high content screening market.
To understand geography trends, Download Sample Report.
For compound profiling applications, many pharmaceutical companies are partnering with contract research organizations to identify potential candidates for drug discovery. The HCS market is highly competitive in nature. The majority of large global players are based out of the United States, and these players have expertise in other biotechnology/medical-technology verticals as well, which helps them in controlling the major market share, through a presence in the allied markets.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Government Funding and Venture Capital Investments Across Developed Markets
4.2.2 Increasing Applications of HCS in Life Science Research
4.2.3 Advancements in Informatic Solutions and Imaging Systems
4.3 Market Restraints
4.3.1 Lower Adoption of HCS Instruments Due to Their High Prices
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
184.108.40.206 Cell Imaging and Analysis Systems
220.127.116.11 Flow Cytometers
18.104.22.168 Reagents and Assay Kits
22.214.171.124 Other Consumables
5.1.4 Other Products
5.2 By Application
5.2.1 Primary and Secondary Screening
5.2.2 Target Identification and Validation
5.2.3 Toxicity Studies
5.2.4 Compound Profiling
5.2.5 Other Applications
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Academic and Government Institutions
5.3.3 Contract Research Organization
5.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.4.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GE Healthcare
6.1.2 Danaher Corporation
6.1.3 Perkinelmer Inc.
6.1.4 Thermo Fisher Scientific Inc.
6.1.5 Becton, Dickinson and Company
6.1.6 Biotek Instruments Inc.
6.1.7 Bio-Rad Laboratories Inc.
6.1.8 Yokogawa Electric Corporation
6.1.9 Merck KGaA
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments